{"id":"acarbose-glucobay-bayg5421","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":"10–20","effect":"Abdominal pain"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"5–10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4299399","moleculeType":"Small molecule","molecularWeight":"645.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acarbose is a competitive inhibitor of alpha-glucosidase enzymes in the small intestine that break down disaccharides and complex carbohydrates into monosaccharides. By delaying carbohydrate digestion and absorption, it reduces the rate at which glucose enters the bloodstream after meals, thereby lowering postprandial glucose excursions in patients with diabetes.","oneSentence":"Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:42.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Postprandial hyperglycemia in type 1 and type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00909051","phase":"","title":"GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03-24","conditions":"Diabetes Mellitus","enrollment":15729},{"nctId":"NCT01685502","phase":"","title":"Special Drug Use Investigation of Glucobay OD","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-11","conditions":"Diabetes Mellitus","enrollment":2289},{"nctId":"NCT01612741","phase":"","title":"Diabetes Treatment With Glucobay in Combination With Metformin","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":19509},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT01388153","phase":"PHASE1","title":"A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06","conditions":"Diabetes Mellitus, Type 2","enrollment":33},{"nctId":"NCT01613105","phase":"","title":"Diabetes Treatment With Glucobay in Combination With Sulfonylurea","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":4564},{"nctId":"NCT01248481","phase":"","title":"GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-09","conditions":"Diabetes Mellitus","enrollment":539},{"nctId":"NCT01554631","phase":"PHASE1","title":"A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":"Diabetes Mellitus, Type 2","enrollment":34},{"nctId":"NCT01728740","phase":"PHASE1","title":"Bioequivalence Study for Acarbose / Metformin FDC","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-09","conditions":"Diabetes Mellitus, Type II","enrollment":40},{"nctId":"NCT01333774","phase":"","title":"Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Diabetes Mellitus","enrollment":423},{"nctId":"NCT01010100","phase":"PHASE3","title":"Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2000-08","conditions":"Diabetes Mellitus","enrollment":204},{"nctId":"NCT01167231","phase":"","title":"Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-05","conditions":"Diabetes Mellitus","enrollment":3310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Acarbose (Glucobay, BAYG5421)","genericName":"Acarbose (Glucobay, BAYG5421)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes. Used for Type 2 diabetes mellitus, Postprandial hyperglycemia in type 1 and type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}